Sign up
Pharma Capital

Summit Therapeutics completes dosing of ezutromid in PhaseOut DMD clinical trial

Initial 24-week results from the 48-week Phase II PhaseOut DMD clinical trial showed a "statistically significant decrease" in muscle inflammation as measured by magnetic resonance spectroscopy transverse relaxation time T2
Small boy with pets
DMD is a muscle disease that affects boys and young men

Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) said ezutromid dosing in patients with Duchenne muscular dystrophy (DMD) for the full 48-week PhaseOut DMD clinical trial has been completed.

Top-line results from the full trial continue to be expected in the third quarter of 2018, the company said in a statement.

WATCH: Summit Therapeutics accelerating preparatory activities for next DMD study

Summit's utrophin modulator, ezutromid, is a potential breakthrough treatment for sufferers of DMD, a fatal wasting disease that affects boys and young men.

Interim data from the trial has already revealed a statistically significant reduction in muscle damage and inflammation in patients after just 24-weeks.

READ: Summit Therapeutics shares jump on initial positive results of clinical trial for DMD​

"We believe the early improvements seen in muscle health in the interim data from PhaseOut DMD indicate ezutromid is reducing DMD disease severity. In the full trial results, we aim to see continued utrophin modulation and sustained changes in magnetic resonance parameters,” said Dr David Roblin, the chief medical officer and president of research & development at Summit.

"These results, if positive, could form the basis of a regulatory filing of ezutromid, bringing this universal treatment to patients more rapidly," he added.


Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.